CoChat

Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages

Open access
Herrera Vielma, Francisca, Quiñones San Martin, Matías, Muñoz-Carrasco, Nicolás, Berrocal-Navarrete, Fernanda, Herrada, Andrés A., Olate-Briones, Alexandra, Zagmutt, Sebastián, Rodríguez-Rodríguez, Rosalía, González, Daniel R., Zúñiga-Hernandez, Jessica · 2026 · Frontiers in Pharmacology

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Hepatic fibrosis is a progressive pathological condition characterized by chronic inflammation and excessive extracellular matrix deposition (ECM), which may progress to cirrhosis and liver failure. Although specialized pro-resolving lipid mediators have emerged as potential therapeutic agents, their role in advanced hepatic fibrosis remains incompletely defined. This study aimed to determine whether Maresin 1 (MaR1), an endogenous pro-resolving lipid mediator, promotes the resolution of hepatic fibrosis and modulates the associated inflammatory response. Hepatic fibrosis was induced in mice and rats using diethylnitrosamine (DEN). Animals were subsequently treated with MaR1 or vehicle. Histological and biochemical parameters, apoptosis and proliferation markers, and immune profiles associated with hepatic macrophages polarization were assessed. Additionally, the expression and subcellular localization of retinoic acid related orphan receptor alpha (RORα) and nuclear factor kappa B (NF-κB p65) were analysed. MaR1 treatment significantly attenuated hepatic fibrosis, reduced the ECM accumulation, and promoted restoration of liver parenchyma, accompanied by decreased hepatocellular injury and enhanced regenerative capacity. MaR1 also induced immune reprogramming, favouring anti-inflammatory and homeostatic macrophage phenotypes. These effects were associated with increased nuclear activation of RORα and modulation of NF-κB signalling pathways. These findings demonstrate that MaR1 promotes the resolution of hepatic fibrosis through macrophage polarization and modulation of the RORα/NF-κB axis. This study advances the understanding of pro-resolving mechanisms in hepatic fibrosis and positions MaR1 as a pharmacologically relevant candidate for the development of targeted antifibrotic therapies in chronic liver disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2026.1826739

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
FIGURE 1 Pharmacokinetics and tissue distribution of MaR1 in SD rats. (A) Concentration-time curve of MaR1 in plasma after a single dose of 4 ng/g MaR1 i.p. (B) Biodistribution of MaR1 in liver, kidney, and heart tissue at 0 (T0) and 30 min (T0.5) after administration. (C) Bioavailability of MaR1 in liver tissue at the end of the experiment (5 weeks) in control, (DEN)-treated, MaR1-treated and MaR1/DEN treated rats. n = 4 animals per group. The asterisk indicates *p < 0.05, **** p < 0.0001.
FIGURE 1 Pharmacokinetics and tissue distribution of MaR1 in SD rats. (A) Concentration-time curve of MaR1 in plasma after a single dose of 4 ng/g MaR1 i.p. (B) Biodistribution of MaR1 in liver, kidney, and heart tissue at 0 (T0) and 30 min (T0.5) after administration. (C) Bioavailability of MaR1 in liver tissue at the end of the experiment (5 weeks) in control, (DEN)-treated, MaR1-treated and MaR1/DEN treated rats. n = 4 animals per group. The asterisk indicates *p < 0.05, **** p < 0.0001.CC BY · PubMed Central
FIGURE 2 Effect of treatment with MaR1 on extracellular matrix deposition in SD rats with chronic liver injury. (A) Experimental design of the murine model showing the induction of chronic liver injury with DEN and treatment with MaR1. (B) Representative micrographs of immunohistochemistry for type I collagen in liver sections and quantification of the percentage of positive areas. At least 20 fields of each sample were analysed at ×400 magnification. The scale bar indicates 20 μm. n = 6 animals per experimental group. (C–H) Panel of representative Western Blots for MMP1, TIMP1, α-SMA, TGF-β, TGF-β RII, and their quantification, normalized to GAPDH. n = 6 per experimental group. The asterisk indicates *p < 0.05, ** p < 0.005, **** p < 0.0001.
FIGURE 2 Effect of treatment with MaR1 on extracellular matrix deposition in SD rats with chronic liver injury. (A) Experimental design of the murine model showing the induction of chronic liver injury with DEN and treatment with MaR1. (B) Representative micrographs of immunohistochemistry for type I collagen in liver sections and quantification of the percentage of positive areas. At least 20 fields of each sample were analysed at ×400 magnification. The scale bar indicates 20 μm. n = 6 animals per experimental group. (C–H) Panel of representative Western Blots for MMP1, TIMP1, α-SMA, TGF-β, TGF-β RII, and their quantification, normalized to GAPDH. n = 6 per experimental group. The asterisk indicates *p < 0.05, ** p < 0.005, **** p < 0.0001.CC BY · PubMed Central
FIGURE 3 Impact of the MaR1 treatment on proliferation and apoptosis in Sprague- Dawley rats with chronic liver injury. (A) Representative H&E sections showing the mitotic activity index (MAI) (left panel) and corresponding magnified images (MAI magnification, middle panel), The corresponding quantification is shown below the columns. (B) Representative TUNEL photomicrographs showing apoptotic cells, with corresponding quantification (right panel). The scale bar indicates 20 μm. n = 6 animals per experimental group. Black arrows indicate dividing cells and apoptotic cells. (C,D) Representative Western blots for cyclin D1 from liver extracts and quantification, normalized to histone H1. n = 6 per experimental group. (E) mRNA levels of Cdk2 (F) mRNA levels of Akt (G) mRNA levels of JNK (H) mRNA levels of ERK. n = 4 per experimental group. The asterisks indicate p < 0.05, * p < 0.005, * p < 0.0005, ** p < 0.0001.
FIGURE 3 Impact of the MaR1 treatment on proliferation and apoptosis in Sprague- Dawley rats with chronic liver injury. (A) Representative H&E sections showing the mitotic activity index (MAI) (left panel) and corresponding magnified images (MAI magnification, middle panel), The corresponding quantification is shown below the columns. (B) Representative TUNEL photomicrographs showing apoptotic cells, with corresponding quantification (right panel). The scale bar indicates 20 μm. n = 6 animals per experimental group. Black arrows indicate dividing cells and apoptotic cells. (C,D) Representative Western blots for cyclin D1 from liver extracts and quantification, normalized to histone H1. n = 6 per experimental group. (E) mRNA levels of Cdk2 (F) mRNA levels of Akt (G) mRNA levels of JNK (H) mRNA levels of ERK. n = 4 per experimental group. The asterisks indicate p < 0.05, * p < 0.005, * p < 0.0005, ** p < 0.0001.CC BY · PubMed Central
FIGURE 4 MaR1 reduced M1 macrophages and increased M2 macrophages in hepatic fibrosis in SD rats. (A) Representative immunofluorescence images of liver sections from control, DEN-treated, MaR1-treated and MaR1/DEN treated rats, stained with anti-CD 86 (red) and anti-CD 206 (green), and quantification of the number of M1 and M2 cells per field. White arrows show an example of M1 and M2 macrophages. n = 3 rats per experimental group, image fields measured per rat >5. Scale bar indicates 50 µm. (B) mRNA levels of CD86 and (C) mRNA levels of CD 206, analysed by qRT-PCR. n = 4 per experimental group. The asterisk indicates *p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. CD86: Cluster of differentiation 86; CD206: cluster of differentiation 206/mannose receptor C-type 1; HPRT: hypoxanthine guanine phosphoribosyltransferase.
FIGURE 4 MaR1 reduced M1 macrophages and increased M2 macrophages in hepatic fibrosis in SD rats. (A) Representative immunofluorescence images of liver sections from control, DEN-treated, MaR1-treated and MaR1/DEN treated rats, stained with anti-CD 86 (red) and anti-CD 206 (green), and quantification of the number of M1 and M2 cells per field. White arrows show an example of M1 and M2 macrophages. n = 3 rats per experimental group, image fields measured per rat >5. Scale bar indicates 50 µm. (B) mRNA levels of CD86 and (C) mRNA levels of CD 206, analysed by qRT-PCR. n = 4 per experimental group. The asterisk indicates *p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. CD86: Cluster of differentiation 86; CD206: cluster of differentiation 206/mannose receptor C-type 1; HPRT: hypoxanthine guanine phosphoribosyltransferase.CC BY · PubMed Central
FIGURE 5 MaR1 induces the polarization of macrophages from a proinflammatory to an anti-inflammatory phenotype in c57bl/6 mice. Flow-cytometry analysis of control, DEN-treated, MaR1-treated and MaR1 + DEN treated C57BL/6 mice for: (A) Identification of M1 and M2 macrophages by surface markers CD11c and CD206 from F4/80hi CD45+ CD11blow (CKs) using density graphs. (B) Identification of M1 and M2 macrophages by surface markers CD11c and CD206 from F4/80hi CD45+ CD11bhi (MoMas) using density plots. (C) M1 percentage of CKs. (D) Percentage of M2 CKs. (E) Percentage of M0 cells in CKs. (F) Percentage of M2 MoMas. (G) Percentage of M1 MoMas. (H) Percentage of M0 cells in MoMas. The asterisk * indicates p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. Data from n = 5 mice per group.
FIGURE 5 MaR1 induces the polarization of macrophages from a proinflammatory to an anti-inflammatory phenotype in c57bl/6 mice. Flow-cytometry analysis of control, DEN-treated, MaR1-treated and MaR1 + DEN treated C57BL/6 mice for: (A) Identification of M1 and M2 macrophages by surface markers CD11c and CD206 from F4/80hi CD45+ CD11blow (CKs) using density graphs. (B) Identification of M1 and M2 macrophages by surface markers CD11c and CD206 from F4/80hi CD45+ CD11bhi (MoMas) using density plots. (C) M1 percentage of CKs. (D) Percentage of M2 CKs. (E) Percentage of M0 cells in CKs. (F) Percentage of M2 MoMas. (G) Percentage of M1 MoMas. (H) Percentage of M0 cells in MoMas. The asterisk * indicates p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. Data from n = 5 mice per group.CC BY · PubMed Central
FIGURE 6 MaR1 modulates inflammation in liver fibrosis through colocalization between RORα and NF-κB in c57bl/6 mice. (A) Quantification of RORα expression by immunofluorescence in control, DEN-treated, MaR1-treated and MaR1/DEN treated C57BL/6 mice. Representative IF micrographs of RORα-positive (red) and cytoplasmic NF-κB p65 (green) liver tissue and overlaid quantification of RORα and NF-κB p65 colocalization (yellow). Pearson’s correlation coefficient and Manders’ coefficient (M2) are shown. At least 20 fields of each sample were analysed at ×400 magnification. Scale bar indicates 50 μm. n = 4 per experimental group. (B) Representative Western blot images. (C) Quantification of RORα protein in cytoplasmic fractions. (D) Quantification of RORα protein in nuclear fractions. (E) Relative mRNA expression of RORα by RT-qPCR. (F) Relative mRNA expression of the RORα target gene BMAL1 by RT-qPCR. (G) NF-κB p65 in cytoplasmic fractions with quantification. (H) NF-κB p65 in nuclear fractions with quantification. (I) Relative mRNA expression of NF-κB by RT-qPCR. (J) Relative mRNA expression of TNF-α by RT-qPCR. (K) Relative mRNA expression of IL-10 by RT-qPCR. (L) Quantification of IκBα and p-IκBα. Western blot levels were normalized to GAPDH, and nuclear levels to histone H1 (n = 6 per experimental group). RT-qPCR values were normalized to HPRT (n = 4 per experimental group). The asterisk indicates *p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. BMAL1: brain and muscle ARNT-like 1; IκBα: inhibitor of kappa B alpha.
FIGURE 6 MaR1 modulates inflammation in liver fibrosis through colocalization between RORα and NF-κB in c57bl/6 mice. (A) Quantification of RORα expression by immunofluorescence in control, DEN-treated, MaR1-treated and MaR1/DEN treated C57BL/6 mice. Representative IF micrographs of RORα-positive (red) and cytoplasmic NF-κB p65 (green) liver tissue and overlaid quantification of RORα and NF-κB p65 colocalization (yellow). Pearson’s correlation coefficient and Manders’ coefficient (M2) are shown. At least 20 fields of each sample were analysed at ×400 magnification. Scale bar indicates 50 μm. n = 4 per experimental group. (B) Representative Western blot images. (C) Quantification of RORα protein in cytoplasmic fractions. (D) Quantification of RORα protein in nuclear fractions. (E) Relative mRNA expression of RORα by RT-qPCR. (F) Relative mRNA expression of the RORα target gene BMAL1 by RT-qPCR. (G) NF-κB p65 in cytoplasmic fractions with quantification. (H) NF-κB p65 in nuclear fractions with quantification. (I) Relative mRNA expression of NF-κB by RT-qPCR. (J) Relative mRNA expression of TNF-α by RT-qPCR. (K) Relative mRNA expression of IL-10 by RT-qPCR. (L) Quantification of IκBα and p-IκBα. Western blot levels were normalized to GAPDH, and nuclear levels to histone H1 (n = 6 per experimental group). RT-qPCR values were normalized to HPRT (n = 4 per experimental group). The asterisk indicates *p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001. BMAL1: brain and muscle ARNT-like 1; IκBα: inhibitor of kappa B alpha.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 8

  1. Beljaars, 2014, Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans, Front. Immunol., 5, 109533, 10.3389/FIMMU.2014.00430/BIBTEX · doi:10.3389/fimmu.2014.00430/bibtex
  2. Freedman, 2020, Biosynthesis of the maresin intermediate, 13S,14S-Epoxy-DHA, by human 15-Lipoxygenase and 12-Lipoxygenase and its regulation through negative allosteric modulators, Biochemistry, 59, 1832, 10.1021/acs.biochem.0c00233/suppl_file/bi0c00233_si_001.pdf · doi:10.1021/acs.biochem.0c00233/suppl_file/bi0c00233_si_001.pdf
  3. Li, 2021, Maresin 1 attenuates lipopolysaccharide-induced acute kidney Injury via inhibiting NOX4/ROS/NF-κB pathway, Front. Pharmacol., 12, 782660, 10.3389/FPHAR.2021.782660/BIBTEX · doi:10.3389/fphar.2021.782660/bibtex
  4. Pawlak, 2015, Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, J. Hepatology, 62, 720, 10.1016/j.jhep.2014.10.039/asset/564df50d-33ea-4270-a683-3de59ea00476/main.assets/gr3.jpg · doi:10.1016/j.jhep.2014.10.039/asset/564df50d-33ea-4270-a683-3de59ea00476/main.assets/gr3.jpg
  5. Rodríguez, 2021, Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation, Cells, 10, 3406, 10.3390/cells10123406/s1 · doi:10.3390/cells10123406/s1
  6. Shamsan, 2024, The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review, Front. Med., 11, 1389329, 10.3389/fmed.2024.1389329/pdf · doi:10.3389/fmed.2024.1389329/pdf
  7. Zhang, 2022, An M0 macrophage-related prognostic model for hepatocellular carcinoma, BMC Cancer, 22, 1, 10.1186/s12885-022-09872-y/figures/8 · doi:10.1186/s12885-022-09872-y/figures/8
  8. Zhu, 2016, Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis, Mol. Neurobiol., 53, 2733, 10.1007/s12035-015-9544-0/figures/9 · doi:10.1007/s12035-015-9544-0/figures/9

Cited by

See all 2

Metadata

Authors
Herrera Vielma, F., Quiñones San Martin, M., Muñoz-Carrasco, N., Berrocal-Navarrete, F., Herrada, A. A., Olate-Briones, A., Zagmutt, S., Rodríguez-Rodríguez, R., González, D. R., & Zúñiga-Hernandez, J.
Affiliations
  • Pharmacology Laboratory, Biomedical Sciences Department, Faculty of Health Sciences, University of Talca
  • Universidad de Talca (CL)
  • University of Concepción (CL)
  • Lymphatic Vasculature and Inflammation Research Laboratory, Department of Clinical Biochemistry and Immunology, Pharmacy Faculty, Universidad de Concepción
  • Universitat Internacional de Catalunya (ES)
  • Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya
Venue
Frontiers in Pharmacology
Published
2026-04-27
Volume
17
Pages
1826739-1826739
ISSN
1663-9812 (ISSN-L)
OpenAlex
W7156374301
Cited by
2
References
58
Citations by year
2026: 2
FWCI
7.96
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
maresin 1, liver fibrosis, RORα, NF-κB signaling, hepatic macrophages, macrophage polarization, specialized pro-resolving mediators, extracellular matrix deposition, antifibrotic therapy, chronic liver disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages. https://app.cochat.ai/papers/10.3389/fphar.2026.1826739
The paper
Herrera Vielma, F., Quiñones San Martin, M., Muñoz-Carrasco, N., Berrocal-Navarrete, F., Herrada, A. A., Olate-Briones, A., Zagmutt, S., Rodríguez-Rodríguez, R., González, D. R., & Zúñiga-Hernandez, J. (2026). Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1826739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.